All In Biotech

NDA 211950 · Bausch and Lomb INC

Xipere

Triamcinolone Acetonide · Injection · Corticosteroid

Last checked: Nov 20, 2026Latest source record: May 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Oct 22, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

692

135 Phase 3, 52 recruiting

FAERS reports

24,536

13,112 serious, 3,174 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2025.

XIPERE ® (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for the treatment of macular edema associated with uveitis. XIPERE ® is a corticosteroid indicated for the treatment of macular edema associated with uveitis. ( 1 )

Mechanism: Triamcinolone acetonide is a synthetic glucocorticoid (glucocorticoids are often referred to as corticosteroids) with immunosuppressive and anti-inflammatory activity. The primary mechanism of action for triamcinolone acetonide is as a corticosteroid hormone receptor agonist.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XIPERE · TRIAMCINOLONE ACETONIDE 40MG/ML · SUSPENSION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Triamcinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 692 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,821
  • off label use2,879
  • pruritus2,715
  • rash2,558
  • pain2,133
  • fatigue2,033
  • nausea1,945
  • product use in unapproved indication1,739
  • diarrhoea1,704
  • vomiting1,703
  • condition aggravated1,678
  • headache1,621

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200471
200558
200640
200780
2008116
2009109
2010113
2011177
2012175
2013203
2014227
2015465
2016633
2017802
20181,050
20191,206
20201,470
20211,789
20222,312
20232,747
20243,545
20253,865
20263,283

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xipere (Triamcinolone Acetonide/PF)

2024 spending

$22K

Beneficiaries

n/a

11 claims

Per beneficiary

n/a

$2,014.64 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$21,758

Part B: Xipere (Triamcinolone Acetonide/PF) · HCPCS J3299

2024 spending

$3.4M

Beneficiaries

1,391

2,185 claims

Per beneficiary

$2,437

2024 ASP limit $48.54 per unit

View as table
YearSpending
2020$0
2021$0
2022$474,242
2023$1,980,830
2024$3,390,120

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 990 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.